Alternatives to Apoha

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

Cultivating wood directly into its final shape, 10,000x faster than forestry.

Developing and industrializing cellulose-based superabsorbent materials as a fossil-free and biodegradable alternative.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

AI safety and research company building reliable, interpretable, and steerable AI systems.

Building foundational AI superintelligence to accelerate scientific knowledge discovery and breakthroughs across complex domains.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Global supplier of life science research tools, including antibodies, reagents, and assays.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A vertically-integrated procurement platform for the life sciences industry.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

A global leader in clinical pharmacology and bioanalytical sciences.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

BreezeBio is a genetic medicine company developing a pipeline of precision therapeutics.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

Developing novel immunotherapies and diagnostics for cancer.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

Developing gene editing therapies to lower cholesterol.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

AI-driven biotech company engineering novel proteins for therapeutics and sustainability.

AI-powered knowledge discovery for life sciences.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.

Engineering scalable gene therapies for broader patient populations.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Developing highly targeted, small molecule medicines.

AI-powered antibody discovery platform.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

Developing oral small molecule medicines for immunological and chronic diseases.

Developing ultrasound-mediated nonviral genetic medicines.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Pioneering vision restoration therapies for severe retinal degenerations.

Develops nanostructured sensor chips for rapid pathogen identification in food.

Turning CO2 into cellulose for textiles using an innovative, carbon-negative enzymatic process.

Developing novel therapies to reverse aging and extend lifespan.

Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity.

Advancing next-generation mRNA medicines.

AI-powered antibody discovery platform.

A biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services.

Developing high-performance, compostable foams from bacterial cellulose to replace fossil-based plastics.

A full-stack spatial biology company.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.